You are here

Article Text

Article menu
Download PDFPDF
Commentary
Viral entry inhibition: too late for hepatitis C, but promising for other viral infections

https://doi.org/10.1136/gutjnl-2014-307452

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests The author has received research grants from Gilead Sciences. He has served as an advisor for Abbvie, Achillion, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Idenix, Janssen, Merck, Novartis, and Roche.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles